Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
NCT01953926
Terminated
This is an open-label, multicenter, multinational, Phase 2 basket study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in participants with HER (EGFR, HER2) mutation-positive solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: Seattle Cancer Care Alliance, Seattle, Washington
Conditions: Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Register for Updates
RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
NCT03189914
Completed
This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer. After completion of the Phase 1 portion, a Phase 2a study will be conducted using a 2 stage, open-label design, of RX 3117 and Abraxane® in combination to treat subjects with metastatic pancreatic cancer as first line therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: Rexahn Site, Spokane, Washington
Conditions: Metastatic Pancreatic Cancer
Register for Updates
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
NCT02599324
Completed
The purpose of this study is to evaluate the safety, tolerability, and efficacy of single agent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel, docetaxel, pembrolizumab or cetuximab in selected advance gastrointestinal and genitourinary tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2023
Locations: Virginia Mason Medical Center /ID# 1128-0005, Seattle, Washington +2 locations
Conditions: Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Advanced Gastric Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
Register for Updates
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
NCT01325441
Completed
This is an open label, single arm phase 1 dose escalation study and phase 2 study of BBI608 in combination with paclitaxel in patients with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Compass Oncology- Northwest Cancer Specialists, Vancouver, Washington
Conditions: Cancer
Register for Updates
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
NCT02993731
Completed
This is a randomized, open-label, multi-center, phase 3 study of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine for adult patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: The Everett Clinic, Everett, Washington +1 locations
Conditions: Carcinoma, Pancreatic Ductal
Register for Updates
A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
NCT02178956
Completed
The purpose of this study is to find out whether it is better to receive a new drug, BBI608, in addition to paclitaxel chemotherapy or better to receive paclitaxel chemotherapy alone as second line treatment for gastric and gastroesophageal junction cancer after prior first line platinum and fluoropyrimidine based chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Virginia Mason Medical Center, Seattle, Washington +1 locations
Conditions: Gastric Cancer, Gastroesophageal Junction Cancer
Register for Updates
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT04329949
Terminated
This is a Phase 3, open-label study to evaluate the objective response rate (ORR), in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with relacorilant in combination with nab-paclitaxel, according to blinded independent central review.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: Site #173, Seattle, Washington
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
The Chocolate Touch Study
NCT02924857
Active Not Recruiting
The Chocolate Touch study is a randomized, multi-center, prospective, adaptive study, designed to show sufficient safety and effectiveness of the Chocolate Touch™ for use in superficial femoral or popliteal arteries with the intention of obtaining regulatory approval to market this device in the United States
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: Swedish Medical Center, Seattle, Washington
Conditions: Intermittent Claudication, Ischemia, Peripheral Artery Disease (PAD)
Register for Updates
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
NCT04729608
Terminated
This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination with PAC in patients with platinum resistant recurrent ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: Swedish Cancer Institute, Seattle, Washington +1 locations
Conditions: Platinum-resistant Ovarian Cancer
Register for Updates
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
NCT03197935
Completed
This is a global Phase III, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (anti-programmed death-ligand 1 \[anti-PD-L1\] antibody) and nab-paclitaxel followed by doxorubicin and cyclophosphamide (nab-pac-AC), or placebo and nab-pac-AC in participants eligible for surgery with initial clinically assessed triple-negative breast cancer (TNBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2023
Locations: Cancer Care Northwest, Spokane, Washington
Conditions: Triple-negative Breast Cancer
Register for Updates
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
NCT03748134
Completed
This is a randomized, double-blind multi-center, phase III study comparing the efficacy and safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in subjects with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma. After the interim analysis conducted by the iDMC, an open-label assignment of experimental arm therapy will continue in regions outside of China, in order to further evaluate the efficacy and safety of sintilim... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/22/2023
Locations: Northwest Cancer Specialists, P.C., Vancouver, Washington
Conditions: Esophageal Squamous Cell Carcinoma
Register for Updates
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
NCT03611556
Completed
The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.
Gender:
ALL
Ages:
Between 18 years and 101 years
Trial Updated:
09/08/2023
Locations: Research Site, Seattle, Washington
Conditions: Carcinoma, Metastatic Pancreatic Adenocarcinoma
Register for Updates